Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of “Hold” by Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has received a consensus rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $5.4286.

A number of brokerages have commented on GOSS. Royal Bank Of Canada upgraded Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Wedbush restated a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. HC Wainwright reduced their target price on Gossamer Bio from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Finally, Leerink Partners lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th.

Gossamer Bio Stock Performance

Shares of GOSS opened at $0.35 on Friday. The company has a 50-day simple moving average of $1.43 and a 200-day simple moving average of $2.36. Gossamer Bio has a 52 week low of $0.32 and a 52 week high of $3.87. The firm has a market capitalization of $81.32 million, a P/E ratio of -0.46 and a beta of 2.08.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 351.49%.The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $7.53 million. As a group, equities analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Trading of Gossamer Bio

Several institutional investors have recently made changes to their positions in GOSS. MB Generational Wealth LLC acquired a new position in Gossamer Bio in the third quarter worth about $3,721,000. Corient Private Wealth LLC boosted its holdings in Gossamer Bio by 8.9% during the second quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock valued at $4,543,000 after purchasing an additional 302,200 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Gossamer Bio during the second quarter valued at approximately $53,000. Choreo LLC grew its stake in shares of Gossamer Bio by 58.2% in the 2nd quarter. Choreo LLC now owns 76,111 shares of the company’s stock valued at $94,000 after purchasing an additional 28,000 shares during the period. Finally, Quadrature Capital Ltd bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $117,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.